FDA Grant: Enhancing Opioids System Modeling for Complex Substance Use Interactions

Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
The following types of Higher Education Institutions are always encouraged to apply for FDA support as Public or Private Institutions of Higher Education:

o Hispanic-serving Institutions

o Historically Black Colleges and Universities (HBCUs)

o Tribally Controlled Colleges and Universities (TCCUs)

o Alaska Native and Native Hawaiian Serving Institutions

o Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
For-Profit Organizations

Small Businesses
For-Profit Organizations (Other than Small Businesses)
Governments

State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)
U.S. Territory or Possession
Other

Independent School Districts
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Faith-based or Community-based Organizations
Regional Organizations

The purpose of this funding opportunity is to expand on the FDA’s modeling efforts to more comprehensively address fentanyl, stimulants and polysubstance use and their interactive effects on opioids use, misuse, use disorder, addiction treatment, and associated outcomes. The primary purpose of this project is to capture the dynamics of and interactions between stimulant or polysubstance use and opioid overdose deaths, as an important emerging aspect of the opioids crisis. The research should also seek to quantify how polysubstance use and synthetic opioids may influence the effects of harm reduction approaches and other potential overdose-prevention strategies. A secondary purpose of the research is to identify and implement feasible approaches for incorporating mental health into part of FDA’s modeling effort.